Across TCGA pan-cancer cohorts, XRCC4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XRCC4 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher XRCC4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated XRCC4 expression acts as an unfavorable survival marker.
KICH, LUSC, and LUAD are the cancer types where XRCC4 Mutation most reproducibly stratifies survival.